• SpectraCure secured a Canadian patent covering an IDOSE-related method to detect tissue bleeding and compensate to maintain accurate laser light delivery.
• The technique targets more consistent dosing in photodynamic therapy for prostate cancer, aiming to improve treatment effectiveness while limiting damage to healthy tissue.
• Canada was the final jurisdiction in its filing set, following prior grants in the US, Europe, China, and Japan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpectraCure AB (publ) published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.